Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03629717 · ClinicalTrials.gov registry record · Early Phase 1
RANKL Inhibition and Breast Tissue Biomarkers
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03629717 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT03629717, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be developed. The investigators propose to investigate the effect of RANKL inhibition with denosumab on breast tissue markers in high-risk premenopausal women with dense breasts. Study findings could provide robust evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal breast cancer prevention.
Interventions
- PROCEDURE Blood draw
- DRUG Denosumab
- DRUG Calcium
- DRUG Vitamin D
- PROCEDURE Ultrasound-guided core needle biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2018-12-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03629717
The ClinicalTrials.gov registry entry for NCT03629717 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT03629717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03629717 about?
NCT03629717 is a clinical study titled "RANKL Inhibition and Breast Tissue Biomarkers". A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be developed. The investigators propose to investigate the effect of RANKL in...
What is the current status of trial NCT03629717?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-06-01. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03629717?
The interventions under investigation include: Blood draw (PROCEDURE), Denosumab (DRUG), Calcium (DRUG), Vitamin D (DRUG), Ultrasound-guided core needle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03629717?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.